ACTRN12614001105639招募中未知
Fit4Two - Usability and initial efficacy testing of a website-delivered behaviour change intervention designed to promote physical activity among pregnant women.
Central Queensland Medicare Local0 个研究点目标入组 64 人开始时间: 2014年10月17日最近更新:
适应症
试验速览
- 阶段
- 未知
- 状态
- 招募中
- 发起方
- 入组人数
- 64
研究概览
简要总结
暂无简介。
研究设计
- 研究类型
- Interventional
- 分配方式
- Randomised controlled trial
- 主要目的
- Educational / counselling / training
- 盲法
- Blinded (masking used)
入排标准
- 年龄范围
- 18 Years 至 o limit（—）
- 性别
- Female
入选标准
- •Eligibality Criteria:
- •must be currently pregnant
- •must be 18+ years of age
- •must be able to read and write in english
- •must be between 10-20 weeks gestation
- •must be considered healthy and free of pregancy contraindications, or have medical approval to participate
排除标准
- •Exclusion Criteria:
- •not currently pregnant
- •not 18+ years of age
- •not able to read and write in english
- •not between 10-20 weeks gestation
- •not considered healthy and free of pregancy contraindications, or have medical approval to participate
研究者
相似试验
尚未招募
不适用
Fit4Two: Feasibility, acceptability and efficacy of a tailored eHealth lifestyle behaviours intervention for pregnant women integrated into clinical practice – a randomised controlled trialpregnancyphysical activitynutritionACTRN12618000610235Central Queensland University80
招募中
不适用
Fit4Two: Feasibility, acceptability and efficacy of a tailored eHealth physical activity intervention for pregnant women integrated into clinical practice – a randomised controlled trialPregnancyPhysical ActivityACTRN12617001489381CQUniversity150
已完成
不适用
A pilot trial to analyze the usability, validity and safety of an interventional health app program (Patronus prehab app) for the structured prehabilitation of patients before major surgical interventions: PROTEGO MAXIMADRKS00026985Goethe-Universität Frankfurt391
已完成
不适用
Digital Diabetes ProjectDiabetesISRCTN57929056niversity of the Highlands and Islands (UK)45
进行中（未招募）
1 期
A Phase II study to assess efficacy and safety of a combination chemotheraphy in first-line treatment with Xeloda + Oxaliplatin + Avastin or Xeloda + Irinotecan + Avastin. At progression of disease (second-line treatment) patient will receive Xeloda + Oxaliplatin + Avastin when received Xeloda + Irinotecan + Avastin in first-line or:At progression of disease (second-line treatment) patient will receive Xeloda + Irinotecan + Avastin if recieved Xeloda + Oxaliplatin + Avastin in first-line.EUCTR2011-002191-16-ATMedizinische Universität Wien, Univ.Klink f. Innere Medizin I120